Nutriband Inc
NTRB
View Detailed Chart
7.220USD
-0.040-0.55%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
79.96MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.55%
5 Days
+0.98%
1 Month
+16.08%
6 Months
+10.40%
Year to Date
+53.29%
1 Year
+28.93%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
15.000
Target Price
+106.61%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.14M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 133.81.
Undervalued
The company’s latest PE is -7.97, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 8.87M shares, increasing 5.23% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 199.63K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.68.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Ticker SymbolNTRB
CompanyNutriband Inc
CEOMr. Serguei Melnik
Websitehttps://nutriband.com/
Related Instruments
+1.10%
-0.32%
-0.51%
-0.30%
-0.68%
+0.10%
-0.68%
-10.99%
-0.71%
-0.80%
-0.09%
-0.05%
-0.49%
+1.41%
-0.89%
-2.81%
-0.82%
-0.89%
-1.01%
+14.84%
